Do You Have to Be on Wegovy for Life — or Is There an Exit?

You've hit your target weight. Now what?

Picture this: you've been on Wegovy for a year, you've lost the weight you set out to lose, and you're wondering whether you really need to keep injecting every week indefinitely. It's a fair question, and plenty of people ask it. The short answer is that semaglutide works by continuously signalling satiety through GLP-1 receptors, once you stop, those signals fade. For most people, appetite returns to something close to its pre-treatment baseline.

The evidence for this is clear. The STEP 1 extension trial followed participants who had completed 68 weeks of semaglutide 2.4mg and then stopped. Within 52 weeks of stopping, participants regained on average around two thirds of the weight they had lost, and cardiometabolic markers largely returned to pre-treatment levels too. You can read the detail in the STEP 1 trial paper, published in the New England Journal of Medicine. That is not a failing of the drug; it reflects the biology of a chronic condition. Obesity is not a short-term problem that medication corrects once and then retreats from.

None of this means everyone must stay on Wegovy permanently, and if you are asking whether Wegovy is for life, it means stopping is a decision that deserves proper thought, ideally with your prescriber rather than a sudden choice made because a pen ran out.

What the NHS two-year limit actually means

If you are on Wegovy through an NHS specialist weight management service, there is a formal time boundary to be aware of. NICE's appraisal of semaglutide (TA875) recommends it for a maximum of two years within that pathway. At that point, treatment is reviewed and, in most cases, stopped under NHS commissioning rules. The limit exists partly because the cost-effectiveness modelling is based on a two-year treatment window, not because two years is proven to be sufficient for everyone.

Private prescribing operates differently. There is no regulatory cap on duration for private patients. What there is instead is an obligation on the prescriber to review clinical suitability regularly, and at a service like ours, that review happens before every repeat order. If long-term treatment makes clinical sense, it continues. If circumstances change, the prescriber adjusts. That ongoing scrutiny is not optional; it is how responsible prescribing works for a medicine like Wegovy.

A practical habit worth building now: once a month, spend thirty seconds noting your current weight and how your appetite has shifted since starting treatment. That log is genuinely useful at your next clinical review, a concrete record rather than a rough impression.

Can people come off Wegovy and keep the weight off?

Some do. The people most likely to sustain weight loss after stopping are those who used the period of reduced appetite to reshape their eating patterns and build consistent activity habits. The medication buys time and reduces the biological noise of hunger, what happens in that window matters. A lower-calorie diet, adequate protein, and regular movement do not prevent weight regain on their own once semaglutide is stopped, but they narrow the gap considerably compared with reverting to previous patterns entirely.

Stopping abruptly is generally not recommended. If you and your prescriber agree that coming off Wegovy is the right move, a gradual step-down approach is far more common than simply stopping at maintenance dose. That is a conversation for your clinical team, guided by the patient information leaflet. Questions about whether staying on Wegovy long term is right for you are best explored in a proper consultation rather than resolved by reading forums. You can also look at how different weight-loss approaches compare if you are trying to build a fuller picture before speaking to a prescriber.

Side effects are sometimes a reason people consider stopping. Bloating and digestive discomfort are common early on (gastric symptoms like a gassy stomach usually settle with time) but if they persist or affect quality of life, that is worth raising at your next review rather than quietly stopping.

Thinking about treatment duration before you start

Duration is worth raising at the very beginning, not six months in. When our prescribers review a new consultation, they consider not just whether Wegovy is clinically suitable right now but also what a realistic treatment plan looks like given that person's health history, comorbidities and goals. For many people, semaglutide is genuinely a long-term medicine, similar in concept to blood-pressure medication, which few people expect to take for only a year. For others, a fixed course alongside substantial lifestyle change may be the more appropriate framing.

Neither answer is wrong in principle. What is wrong is not having the conversation. If you are weighing up whether long-term use is appropriate for your situation, or you want to explore what a clinically supervised treatment plan could look like for you, that is exactly the kind of question a free consultation is designed to answer. A prescriber will look at the whole picture, not just the number on the scales.